Trials / Completed
CompletedNCT00116155
Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer
A Phase I/II Dose Finding Trial of the Intravenous Injection of CV787, a Prostate-Specific Antigen Cytolytic Adenovirus, in Patients With Hormone Refractory Metastatic Prostate Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Cell Genesys · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
This is a multi-center, open-label, dose finding study of CV787 adenovirus in patients with hormone refractory metastatic prostate cancer. Patients will receive treatment intravenously at one of up to nine dose levels, each containing three to six patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CV787 (CG7870) |
Timeline
- First posted
- 2005-06-28
- Last updated
- 2005-06-28
Source: ClinicalTrials.gov record NCT00116155. Inclusion in this directory is not an endorsement.